Thrombolytic profiles of clot-targeted plasminogen activators: Parameters determining potency and initial and maximal rates

Circulation

Volumn 87, Issue 3, 1993, Pages 1007-1016

  Holvoet, Paul ^a   Dewerchin, Maria ^a   Stassen, Jean Marie ^a   Lijnen, Henri Roger ^a   Tollenaere, Tom ^b   Gaffney, Patrick J ^c   Collen, Désiré ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Acute myocardial infarction; Kinetics; Plasminogen activators; Thrombolysis

Indexed keywords

ALTEPLASE; MONOCLONAL ANTIBODY 12B3; MONOCLONAL ANTIBODY 15CS; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BLOOD CLOT; BLOOD CLOT LYSIS; CHEMICAL REACTION KINETICS; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FIBRINOLYSIS; HAMSTER; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RABBIT;

ANIMAL; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; FIBRIN; FIBRINOLYTIC AGENTS; HAMSTERS; HUMAN; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; RABBITS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 0027535088     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.87.3.1007     Document Type: Article

References (38)

1. Haber E, Quertermous T, Matsueda GR, Runge MS: Innovative approaches to plasminogen activator therapy. Science 1989;243: 51-56
2. Rosebrough SF, Kudryk B, Grossman ZD, McAfee JG, Subramanian G, Ritter-Hrncirik CA, Witanowski LS, Tillapaugh-Fay G: Radioimmunoimaging of venous thrombi using iodine-131 monoclonal antibody. Radiology 1985;156:515-517
3. Hui KY, Haber E, Matsueda GR: Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin, but not fibrinogen. Science 1983;222:1129-1132
4. Holvoet P, Stassen JM, Hashimoto Y, Spriggs D, Devos P, Collen D: Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits. Thromb Haemost 1989;61:307-313
5. Hashimoto Y, Stassen JM, Leclef B, De Roo M, Vandecruys A, Melin J, Verhoeven-Mester D, Trouet A, Collen D: Thrombus imaging with 123I-labeled F(ab′)2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model. Radiology 1989;171: 223-226
6. Rosebrough SF, McAfee JG, Grossman ZD, Kudryk BJ, Ritter-Hrncirik CA, Witanowski LS, Maley BL, Bertrand EA, Gagne GM: Thrombus imaging: A comparison of radiolabeled GC4 and T2G1s fibrin-specific monoclonal antibodies. J Nucl Med 1990;31: 1048-1054
7. Tymkewycz PM, Creighton LJ, Gascoine PS, Zanelli GD, Webbon PM, Gaffney PJ: Imaging of human thrombi in the rabbit jugular vein: I. Comparison of two fibrin-specific monoclonal antibodies. Thromb Res 1989;54:411-421
8. Bode C, Matsueda G, Hui KY, Haber E: Antibody-directed urokinase: A specific fibrinolytic agent. Science 1985;229:765-767
9. Bode C, Runge MS, Newell JB, Matsueda GR, Haber E: Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 1987;262:10819-10823
10. Runge MS, Bode C, Matsueda GR, Haber E: Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci U S A 1987;84:7659-7662
11. Runge MS, Bode C, Matsueda GR, Haber E: Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 1988;27: 1153-1157
12. Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T: Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci U S A 1987;84:6904-6908
13. Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D: Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989;185:141-149
14. Collen D, Dewerchin M, Stassen JM, Kieckens L, Lijnen HR: Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989;3:197-202
15. Collen D, Dewerchin M, Rapold H, Lijnen HR, Stassen JM: Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin, in a baboon venous thrombosis model. Circulation 1990;82:1744-1753
16. Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw SY, Huang PL, Chou CC, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E: A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci U S A 1991;88:10337-10341
17. Van Damme AM, Dewerchin M, Lijnen HR, Bernar H, Bulens F, Nelles L, Collen D: Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Eur J Biochem 1992;205:139-146
18. Dewerchin M, Van Damme A-M, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D: Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Thromb Haemost 1992;68:170-179
19. Chen F, Haber E, Matsueda GR: Availability of the Bβ (15-21) epitope on cross-linked human fibrin and its plasmic degradation products. Thromb Haemost 1992;67:335-340
20. Tymkewycz PM, Gascoine PS, Gaffney PJ: A monoclonal antibody (MAB) to an A-alpha chain epitope which is exposed only on the surface of fibrin. (abstract) Thromb Haemost 1989;62:478
21. Carlsson J, Drevin H, Axen R: Protein thiolation and reversible protein-protein conjugation: N-Succinimidyl 3-(2-pyridyldithio) propionate, a new heterobifunctional reagent. Biochem J 1978;173: 723-727
22. Declerck PJ, Van Keer L, Verstreken M, Collen D: An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Thromb Haemost 1992;67:95-100
23. Bolton AE, Hunter WM: The use of antisera covalently coupled to agarose, cellulose and sephadex in radioimmunoassay for proteins and haptens. Biochim Biophys Acta 1973;329:318-330
24. Holvoet P, Cleemput H, Collen D: Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985;54:684-687
25. Hogg PJ, Johnston SC, Bowles MR, Pond SM, Winsor DJ: Evaluation of equilibrium constants for antigen-antibody interactions by solid-phase immunoassay. The binding of paraquat to its elicited mouse monoclonal antibody. Mol Immunol 1987;24:797-801
26. Astrup T, Muellertz S: Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952;40:346-351
27. 2 prostaglandin endoperoxide receptor blockade combined in one molecule - II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989;61:43-49
28. Marquart DW: An algorithm for least-squares estimation of non-linear parameters. J Soc Int Appl Math 1963;11:431-441
29. Gibaldi M, Perrier D (eds): Pharmacokinetics. New York, Marcel Dekker Inc, 1983, pp 45-111
30. Collen D, Stassen JM, Verstraete M: Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983;71:368-376
31. Giles AR: Guidelines for the use of animals in biomedical research. Thromb Haemost 1987;58:1078-1084
32. Stassen JM, Vanlinthout I, Lijnen HR, Collen D: A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990;4:15-21
33. Clozel JP, Tschopp T, Luedin E, Holvoet P: Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation 1989;79:125-133
34. Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM: Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains in a hamster pulmonary embolism model. Thromb Haemost 1991;65:174-180
35. Collen D: On the future of thrombolytic therapy in acute myocardial infarction, in Braunwald E, Haber E (eds): Thrombolysis: Basic Contributions and Clinical Progress. St Louis, Mosby Year Book, 1991, pp 315-331
36. PRIMI Trial Study Group: Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-868
37. Korninger C, Collen D: Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981;46:561-565
38. Lijnen HR, De Wreede K, Demarsin E, Collen D: Biological and thrombolytic properties of proenzyme and active forms of human urokinase: IV. Variability in fibrinolytic response of plasma of several mammalian species. Thromb Haemost 1984;52:31-33